Corporate
Lilly Stock Drops 4% as FDA Delays Obesity Pill, Handing Novo Crucial Head Start
Jan 15
You're signed outSign in or to get full access.
ELI LILLY & (LLY) Earnings Call Transcripts
Browse quarterly earnings call transcripts for ELI LILLY &.
Q3 2025
Oct 30, 2025
Q2 2025
Aug 7, 2025
Q1 2025
May 1, 2025
Q4 2024
Feb 6, 2025
Q3 2024
Oct 30, 2024
Q2 2024
Aug 8, 2024
Recent News about ELI LILLY &
Policy & Geopolitics
FDA Removes Suicide Warnings From Blockbuster Weight-Loss Drugs Wegovy and Zepbound
Jan 13
Deals & Capital Markets
Eli Lilly Eyes €15 Billion Abivax Takeover as Pharma M&A Heats Up
Jan 12
Deals & Capital Markets
Aktis Oncology Raises $318M in 2026's First Biotech IPO, Lilly Takes $100M Stake
Jan 9
Corporate
Lilly's Zepbound-Taltz Combo Delivers 40x Response Rate in First-of-Its-Kind Arthritis-Obesity Trial
Jan 8
Deals & Capital Markets
Eli Lilly Nears $1B+ Ventyx Deal as TYK2 Arms Race Heats Up
Jan 7